Marcia Cruz-Correa/cancer.gov
Jan 26, 2025, 14:23
Marcia Cruz-Correa: Gastric Cancer 1st line therapy biomarkers at ASCO GI 2025
Marcia Cruz-Correa, Chief Medical Officer at PanOncology Trials, shared a post on X:
“Participating in ASCO GI 2025 Gastric Cancer 1st line therapy biomarkers including HER2, PDL1 and CLDN18 are vital to guide targeted therapy.
Clinical trails are available and integrate these biomarkers.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 18, 2025, 14:17
Aug 18, 2025, 14:13
Aug 18, 2025, 13:53
Aug 18, 2025, 13:48
Aug 18, 2025, 13:30
Aug 18, 2025, 13:06
Aug 18, 2025, 13:03